Is there any role for alpelisib in a patient who has triple positive breast cancer and an activating PIK3CA mutation?
Answer from: Medical Oncologist at Academic Institution
Data are limited for this indication. SOLAR-1 study (André et al., PMID 31091374) was restricted to hormone receptor positive Her2 negative patients. A phase I study of the combination of alpelisib with TDM-1 has been completed (Jain et al., PMID 29850984) and a study of alpelisib in combinat...
Sign in or Register to read more